GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (OTCPK:CFBFF) » Definitions » Cyclically Adjusted Book per Share

Can Fite Biofarma (Can Fite Biofarma) Cyclically Adjusted Book per Share : $0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Can Fite Biofarma's adjusted book value per share for the three months ended in Dec. 2023 was $0.293. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Can Fite Biofarma's average Cyclically Adjusted Book Growth Rate was -6.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Can Fite Biofarma was -2.80% per year. The lowest was -2.80% per year. And the median was -2.80% per year.

As of today (2024-05-25), Can Fite Biofarma's current stock price is $1.88. Can Fite Biofarma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.00. Can Fite Biofarma's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biofarma was 0.50. The lowest was 0.04. And the median was 0.18.


Can Fite Biofarma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted Book per Share Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PB Ratio falls into.



Can Fite Biofarma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Can Fite Biofarma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.293/129.4194*129.4194
=0.293

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.357 99.695 0.463
201406 0.225 100.560 0.290
201409 0.142 100.428 0.183
201412 0.304 99.070 0.397
201503 0.281 99.621 0.365
201506 0.215 100.684 0.276
201509 0.322 100.392 0.415
201512 0.484 99.792 0.628
201603 0.432 100.470 0.556
201606 0.362 101.688 0.461
201609 0.274 101.861 0.348
201612 0.181 101.863 0.230
201703 0.272 102.862 0.342
201706 0.188 103.349 0.235
201709 0.163 104.136 0.203
201712 0.235 104.011 0.292
201803 0.349 105.290 0.429
201806 0.305 106.317 0.371
201809 0.300 106.507 0.365
201812 0.141 105.998 0.172
201903 0.152 107.251 0.183
201906 0.396 108.070 0.474
201909 0.331 108.329 0.395
201912 0.115 108.420 0.137
202003 0.000 108.902 0.000
202006 0.430 108.767 0.512
202009 0.448 109.815 0.528
202012 0.285 109.897 0.336
202103 0.332 111.754 0.384
202106 0.186 114.631 0.210
202109 0.438 115.734 0.490
202112 0.675 117.630 0.743
202203 0.564 121.301 0.602
202206 0.464 125.017 0.480
202209 0.348 125.227 0.360
202212 0.210 125.222 0.217
202303 0.398 127.348 0.404
202306 0.322 128.729 0.324
202309 0.246 129.860 0.245
202312 0.293 129.419 0.293

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Can Fite Biofarma  (OTCPK:CFBFF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biofarma was 0.50. The lowest was 0.04. And the median was 0.18.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Can Fite Biofarma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry
Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019